Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Sanfilippo Syndrome Type A (MPS IIIA) (2 trials)
- Main trialPhase 1/2
- “MPS IIIA, also known as Sanfilippo A, is an inherited lysosomal storage disease (LSD). MPS IIIA is caused by a deficiency in sulfamidase, one of the enzymes involved in the lysosomal degradation of the glycosaminoglycan (GAG) heparan sulfate (HS). The natural course of MPS IIIA is characterized by devastating neurodegeneration with initially mild somatic involvement. The aims of the present study is to assess the dose related safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SOBI003, a chemically modified recombinant human (rh) Sulfamidase developed as an enzyme…”In the company’s words, NCT03423186 on ClinicalTrials.gov
- Other names
- Modified recombinant human sulphamidase
Other drugs for Sanfilippo Syndrome Type A (MPS IIIA)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 25 Oct 2019 | A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients | |
| Phase 1/2Completed | 30 Apr 2021 | A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026